Oscar Health shares trade 13% below IPO despite strong growth and AI-driven cost savings.

Oscar Health's stock is trading about 13% below its 2021 IPO price, even though management projects 2026 revenue to be roughly seven times higher than in 2021. Despite the expiration of enhanced ACA subsidies, which was a major concern, Oscar Health grew its membership by around 60%, while the ACA market shrank by about 13%. Looking ahead to 2027, factors like competitor exits, significant price increases, and earnings per share potentially below management targets could lead to a stock rerating. Additionally, Oscar Health's AI-driven cost savings and a substantial tax shield from past losses present upside potential that the market may not fully recognize. The analyst rates Oscar Health as a buy with an expected 25% upside in the base case and up to 64% in a bullish scenario.

Oscar Health's market capitalization stands at $10.59 billion as of October 15, 2026, 22:01 WIB, reflecting its significant presence in the health sector. The stock price on Pluang is currently USD 33.40, down 2.68% for the day, with a trading volume of 5,280,571 shares. These figures highlight active investor interest and liquidity in the stock, complementing the company's growth narrative and potential rerating discussed in the article.